Intermountain CEO Sorenson announces retirement, future plans

Dave Pearson | | Health Exec | Management

Charles Sorenson, MD, the urologic cancer surgeon who has been an executive at Intermountain Healthcare for 18 years and the institution’s CEO since early 2009, will retire the helm in Salt Lake City next October.

But the 64-year-old, who was ranked ninth by Modern Healthcare in its 2015 list of the 50 most influential physician executives, won’t ride out of U.S. healthcare and into the sunset. Instead he will become founding director of the Intermountain Healthcare Leadership Institute.

According to an Intermountain news release, this new entity will house Intermountain’s existing Institute for Healthcare Delivery Research and “provide specialized leadership training programs for physicians and other clinical and operational leaders who have, or are capable of assuming, broader administrative responsibilities locally, nationally, and internationally.”

The 22-hospital, 40,000-employee health system said it plans to conduct a national search for a new CEO. 

Dave Pearson
Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.